PL3277286T3 - Pochodne kwasu żółciowego jako agonisty fxr/tgr5 i sposoby ich stosowania - Google Patents
Pochodne kwasu żółciowego jako agonisty fxr/tgr5 i sposoby ich stosowaniaInfo
- Publication number
- PL3277286T3 PL3277286T3 PL16774118T PL16774118T PL3277286T3 PL 3277286 T3 PL3277286 T3 PL 3277286T3 PL 16774118 T PL16774118 T PL 16774118T PL 16774118 T PL16774118 T PL 16774118T PL 3277286 T3 PL3277286 T3 PL 3277286T3
- Authority
- PL
- Poland
- Prior art keywords
- fxr
- methods
- acid derivatives
- bile acid
- tgr5 agonists
- Prior art date
Links
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140927P | 2015-03-31 | 2015-03-31 | |
| US201662287267P | 2016-01-26 | 2016-01-26 | |
| PCT/US2016/025035 WO2016161003A1 (en) | 2015-03-31 | 2016-03-30 | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| EP16774118.0A EP3277286B1 (en) | 2015-03-31 | 2016-03-30 | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3277286T3 true PL3277286T3 (pl) | 2021-11-08 |
Family
ID=57007583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16774118T PL3277286T3 (pl) | 2015-03-31 | 2016-03-30 | Pochodne kwasu żółciowego jako agonisty fxr/tgr5 i sposoby ich stosowania |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10457703B2 (pl) |
| EP (1) | EP3277286B1 (pl) |
| JP (1) | JP6785788B2 (pl) |
| KR (1) | KR102681304B1 (pl) |
| CN (1) | CN107427527B (pl) |
| AU (1) | AU2016242861B2 (pl) |
| CA (1) | CA2981503C (pl) |
| CY (1) | CY1124404T1 (pl) |
| DK (1) | DK3277286T3 (pl) |
| ES (1) | ES2886766T3 (pl) |
| HR (1) | HRP20211066T1 (pl) |
| HU (1) | HUE054960T2 (pl) |
| IL (1) | IL254288B (pl) |
| LT (1) | LT3277286T (pl) |
| MX (1) | MX379579B (pl) |
| MY (1) | MY192135A (pl) |
| NZ (1) | NZ735126A (pl) |
| PH (1) | PH12017501586B1 (pl) |
| PL (1) | PL3277286T3 (pl) |
| PT (1) | PT3277286T (pl) |
| RS (1) | RS62110B1 (pl) |
| RU (1) | RU2712099C2 (pl) |
| SG (2) | SG11201707263XA (pl) |
| SI (1) | SI3277286T1 (pl) |
| SM (1) | SMT202100593T1 (pl) |
| WO (1) | WO2016161003A1 (pl) |
| ZA (2) | ZA201707212B (pl) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007099398A2 (en) | 2005-09-27 | 2007-09-07 | Naturalite Benelux B.V. | Methods and compositions for treatment of skin |
| CA2966885A1 (en) | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
| HK1244708A1 (zh) | 2014-11-26 | 2018-08-17 | 英安塔制药有限公司 | 作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法 |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| WO2016086115A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
| NZ735126A (en) | 2015-03-31 | 2022-10-28 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| MY196292A (en) * | 2016-01-28 | 2023-03-24 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Steroid Derivative Fxr Agonist |
| US10323061B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
| WO2017147159A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| US10323060B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof |
| EA038580B9 (ru) * | 2016-05-18 | 2021-10-05 | Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. | Агонист fxr, представляющий собой производное стероидов |
| WO2018102418A1 (en) | 2016-11-29 | 2018-06-07 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
| CN108218945B (zh) * | 2016-12-15 | 2021-05-28 | 宁波百纳西药业有限公司 | 去氧胆酸衍生物、其制备方法、药物组合物及用途 |
| CN108218946B (zh) * | 2016-12-15 | 2021-04-16 | 宁波百纳西药业有限公司 | 一种去氧胆酸类化合物、其制备方法及应用 |
| US10472386B2 (en) | 2017-02-14 | 2019-11-12 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR agonists and methods of use thereof |
| CA3058754A1 (en) * | 2017-04-07 | 2018-10-11 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonyl carbamate bile acid derivatives |
| BR112019027458A2 (pt) | 2017-06-23 | 2020-07-07 | Intercept Pharmaceuticals, Inc. | métodos e intermediários para a preparação de derivados de ácidos biliares |
| JP7308811B2 (ja) * | 2017-07-26 | 2023-07-14 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | ステロイド系誘導体ｆｘｒアゴニストの製造方法 |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| WO2021009332A1 (en) | 2019-07-18 | 2021-01-21 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| CA3159163A1 (en) | 2020-01-15 | 2021-07-22 | Raphael Darteil | Use of fxr agonists for treating an infection by hepatitis d virus |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| US12215127B2 (en) | 2020-04-17 | 2025-02-04 | Cornell University | Compositions and methods for profiling of gut microbiota-associated bile salt hydrolase (BSH) activity |
| US12030912B2 (en) * | 2020-05-15 | 2024-07-09 | Brigham Young University | Cationic steroidal antimicrobial compounds with urethane linkages |
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
| JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| CA3204800A1 (en) | 2021-01-14 | 2022-07-21 | Raphael Darteil | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| US20240216364A1 (en) | 2021-04-28 | 2024-07-04 | Enyo Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
| WO2023288123A1 (en) | 2021-07-16 | 2023-01-19 | Interecept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid |
Family Cites Families (144)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1592791A (en) | 1977-01-07 | 1981-07-08 | Radiochemical Centre Ltd | Selenium- or tellurium-containing bile acids and derivatives thereof |
| WO1987002367A2 (en) | 1985-10-18 | 1987-04-23 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
| US5571809A (en) | 1989-04-20 | 1996-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | The treatment of HIV-1 infection using certain pyridodiazepines |
| IT1255449B (it) | 1992-06-30 | 1995-10-31 | Fabio Berlati | Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci. |
| IT1255485B (it) | 1992-08-04 | 1995-11-06 | Erregierre Ind Chim | Processo per preparare gli acidi biliari coniugati con la glicina e relative composizioni terapeutiche per il trattamento dell'insufficienza epatica |
| TW289757B (pl) | 1993-05-08 | 1996-11-01 | Hoechst Ag | |
| TW289020B (pl) | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
| US5541348A (en) * | 1994-03-10 | 1996-07-30 | National Research Council Of Canada | Bile acids for biological and chemical applications and processes for the production thereof |
| JP3696884B2 (ja) | 1994-03-25 | 2005-09-21 | アイソテクニカ、インコーポレーテッド | ジュウテリウム化による薬物の効能の増強 |
| US5646316A (en) | 1994-04-08 | 1997-07-08 | Osteoarthritis Sciences, Inc. | Bile acid inhibitors of metalloproteinase enzymes |
| WO2000066106A2 (en) | 1999-04-30 | 2000-11-09 | The Regents Of The University Of Michigan | Use of benzodiazepines for treating autoimmune diseases induced by apoptosis |
| JPH1160594A (ja) | 1997-08-25 | 1999-03-02 | Sankyo Co Ltd | 胆汁酸誘導体 |
| JP3865890B2 (ja) * | 1997-09-30 | 2007-01-10 | 富士フイルムホールディングス株式会社 | ポジ型感光性組成物 |
| EP1140079B1 (en) | 1998-12-23 | 2009-06-03 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
| US20020132223A1 (en) | 1999-03-26 | 2002-09-19 | City Of Hope | Methods for modulating activity of the FXR nuclear receptor |
| US20020098999A1 (en) * | 2000-10-06 | 2002-07-25 | Gallop Mark A. | Compounds for sustained release of orally delivered drugs |
| EP1343805A4 (en) * | 2000-10-06 | 2005-07-20 | Xenoport Inc | COMPOUNDS DERIVED FROM GALLENIC ACIDS FOR THE PROVISION OF CONTINUING SYSTEMIC CONCENTRATIONS OF MEDICINAL PRODUCTS AFTER ORAL ADMINISTRATION |
| US7138390B2 (en) | 2001-03-12 | 2006-11-21 | Intercept Pharmaceuticals | Steroids as agonists for FXR |
| DE60131967D1 (de) | 2001-08-13 | 2008-01-31 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| CA2482195A1 (en) | 2002-04-12 | 2003-10-23 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| ITMI20021080A1 (it) | 2002-05-21 | 2003-11-21 | Marcello Izzo | Associazioni farmaceutiche per uso topico a base di chelati del ferroinibitori delle metalloproteasi e fattore xiii per il trattamento dell |
| AU2003290796A1 (en) | 2002-11-14 | 2004-06-15 | The Scripps Research Institute | Non-steroidal fxr agonists |
| US7319109B2 (en) | 2002-11-22 | 2008-01-15 | Smith Kline Beecham Corporation | Farnesoid X receptor agonists |
| EP1690538A4 (en) | 2003-12-02 | 2009-02-25 | Shionogi & Co | ISOXAZOLE DERIVATIVE AGONISTIC ACTION AGAINST PEROXISOM PROLIFERATOR ACTIVATED RECEPTOR |
| EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| PT1734970E (pt) | 2004-03-12 | 2015-03-11 | Intercept Pharmaceuticals Inc | Tratamento de fibrose utilizando ligandos de rfx |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| US7705028B2 (en) | 2005-12-19 | 2010-04-27 | Glaxosmithkline Llc | Farnesoid X receptor agonists |
| EP1979329A2 (en) | 2006-01-30 | 2008-10-15 | Exelixis, Inc. | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and methods of use |
| AU2007211279B2 (en) | 2006-02-01 | 2013-02-14 | Brigham Young University | Cationic steroid antimicrobial compositions and methods of use |
| CN101374834B (zh) | 2006-02-03 | 2011-12-14 | 伊莱利利公司 | 用于调节fxr的化合物和方法 |
| CN101395170A (zh) | 2006-02-14 | 2009-03-25 | 英特塞普特药品公司 | 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物 |
| AU2007230991A1 (en) | 2006-03-22 | 2007-10-04 | Syndexa Pharmaceuticals Corporation | Compounds and methods for treatment of disorders associated with ER stress |
| US7846960B2 (en) | 2006-05-24 | 2010-12-07 | Eli Lilly And Company | FXR agonists |
| WO2008002573A2 (en) | 2006-06-27 | 2008-01-03 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions |
| TW200811170A (en) | 2006-06-27 | 2008-03-01 | Sanofi Aventis | Urea derivatives of tropane, their preparation and their therapeutic application |
| WO2008009407A2 (en) | 2006-07-17 | 2008-01-24 | Novartis Ag | Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators |
| NZ598548A (en) | 2006-08-15 | 2013-09-27 | Novartis Ag | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| EP2069177A4 (en) | 2006-09-15 | 2012-12-05 | Volvo Lastvagnar Ab | METHOD FOR ADAPTING AN AUTOMATIC MECHANICAL BOX ON A HEAVYWEIGHT VEHICLE |
| CL2007003035A1 (es) | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
| EP1918281A1 (en) | 2006-11-02 | 2008-05-07 | Laboratorios del Dr. Esteve S.A. | Phenylamino-substituted piperidine compounds, their preparation and use as medicaments |
| CA2672373C (en) | 2006-12-19 | 2011-08-30 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| CA2928178C (en) | 2007-01-19 | 2019-09-10 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
| EP1947108A1 (en) | 2007-01-19 | 2008-07-23 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
| CA2680587A1 (en) | 2007-03-15 | 2008-09-25 | Schering Corporation | Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors |
| CA2689980A1 (en) | 2007-06-13 | 2008-12-24 | Glaxosmithkline Llc | Farnesoid x receptor agonists |
| EP2173174A4 (en) | 2007-07-02 | 2010-08-04 | Glaxosmithkline Llc | FARNESOID X RECEPTOR AGONISTS |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| US8338628B2 (en) | 2007-08-28 | 2012-12-25 | City Of Hope | Method of synthesizing alkylated bile acid derivatives |
| CA2985271A1 (en) | 2007-09-06 | 2009-03-12 | Ohr Pharmaceutical, Inc. | A method for treating diabetes |
| US20090163474A1 (en) | 2007-10-19 | 2009-06-25 | Wyeth | FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases |
| KR101239008B1 (ko) * | 2008-03-31 | 2013-03-04 | 한양대학교 산학협력단 | 바일산 유도체 및 그의 응용 |
| EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
| EP2128158A1 (en) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclic cyclopropyl-substituted FXR binding compounds |
| EA020310B1 (ru) | 2008-07-30 | 2014-10-30 | Интерсепт Фармасьютикалз, Инк. | Модуляторы рецептора tgr5 и их применение |
| CA2738453C (en) | 2008-10-23 | 2017-07-04 | Boehringer Ingelheim International Gmbh | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use |
| US8785488B2 (en) | 2009-02-12 | 2014-07-22 | Exelixis Patent Company Llc | Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity |
| US8329904B2 (en) | 2009-05-12 | 2012-12-11 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2011021645A1 (ja) | 2009-08-19 | 2011-02-24 | 大日本住友製薬株式会社 | ２環性ウレア誘導体、またはその薬学的に許容される塩 |
| EP3050885B1 (en) | 2009-11-05 | 2017-10-18 | GlaxoSmithKline LLC | Benzodiazepine bromodomain inhibitor |
| WO2012087520A1 (en) | 2010-12-20 | 2012-06-28 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| WO2012087521A1 (en) | 2010-12-20 | 2012-06-28 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| CA2842707A1 (en) | 2011-08-04 | 2013-02-07 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of pancreatitis |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| US11154559B2 (en) | 2011-09-29 | 2021-10-26 | Ethicon Endo-Surgery, Inc. | Methods and compositions of bile acids |
| WO2013166176A1 (en) | 2012-05-01 | 2013-11-07 | Catabasis Pharmaceuticals, Inc. | Fatty acid conjugates of statin and fxr agonists; compositions and method of uses |
| ES2822375T3 (es) | 2012-06-19 | 2021-04-30 | Intercept Pharmaceuticals Inc | Preparación de la forma no cristalina del ácido obeticólico |
| US9079935B2 (en) | 2012-08-13 | 2015-07-14 | The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas | Reducing risk of contracting Clostridium-difficile associated disease |
| WO2014036379A2 (en) * | 2012-08-31 | 2014-03-06 | Metselex | Bile acids prevent or abolish progression of parkinson's and related neurodegenerative diseases |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140206657A1 (en) * | 2013-01-18 | 2014-07-24 | City Of Hope | Bile acid analog tgr5 agonists |
| HRP20180931T1 (hr) | 2013-05-14 | 2018-10-05 | Intercept Pharmaceuticals, Inc. | 11-hidroksil-6-supstituirani-derivati žučnih kiselina i njihovi aminokiselinski konjugati kao modulatori receptora za farnezoid x |
| US9540415B2 (en) * | 2013-08-01 | 2017-01-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the farnesoid X receptor and uses in medicine |
| LT3043865T (lt) | 2013-09-11 | 2021-04-26 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Hepatito b viruso infekcijos gydymo būdai ir farmacinė kompozicija |
| US20150112089A1 (en) | 2013-10-22 | 2015-04-23 | Metselex, Inc. | Deuterated bile acids |
| ES2938874T3 (es) | 2014-05-29 | 2023-04-17 | Bar Pharmaceuticals S R L | Derivados de colano para su uso en el tratamiento y/o prevención de enfermedades mediadas por FXR y TGR5/GPBAR1 |
| CA2966885A1 (en) | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
| CN111944006B (zh) | 2014-11-17 | 2021-12-17 | 正大天晴药业集团股份有限公司 | 新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途 |
| US20160176917A1 (en) | 2014-11-26 | 2016-06-23 | Enanta Pharmaceuticals, Inc. | Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| WO2016086115A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
| HK1244708A1 (zh) | 2014-11-26 | 2018-08-17 | 英安塔制药有限公司 | 作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法 |
| EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| BR112017011972A2 (pt) | 2014-12-18 | 2017-12-26 | Novartis Ag | derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais |
| RU2017130466A (ru) | 2015-02-11 | 2019-03-12 | Энанта Фармасьютикалс, Инк. | Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| NZ735126A (en) | 2015-03-31 | 2022-10-28 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| CN111116699B (zh) | 2015-04-28 | 2023-02-28 | 江苏豪森药业集团有限公司 | 胆酸衍生物及其制备方法和医药用途 |
| CN106083978A (zh) | 2015-04-28 | 2016-11-09 | 上海迪诺医药科技有限公司 | 磺酰基氨基羰基衍生物、其药物组合物及应用 |
| CN111574577B (zh) | 2015-04-29 | 2025-02-25 | 正大天晴药业集团股份有限公司 | 鹅去氧胆酸衍生物 |
| PL3310801T3 (pl) | 2015-06-19 | 2021-11-22 | Intercept Pharmaceuticals, Inc. | Modulatory tgr5 i sposoby ich stosowania |
| BR112018002499A2 (pt) | 2015-08-07 | 2018-09-18 | Intercept Pharmaceuticals Inc | método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica |
| CN105175473B (zh) | 2015-08-19 | 2018-12-21 | 丽珠医药集团股份有限公司 | 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途 |
| CN106478759A (zh) | 2015-08-31 | 2017-03-08 | 陕西合成药业股份有限公司 | 奥贝胆酸衍生物及其制备方法和用途 |
| CN106518946A (zh) | 2015-09-10 | 2017-03-22 | 上海迪诺医药科技有限公司 | 磺酰脲衍生物、其药物组合物及应用 |
| KR20180052756A (ko) | 2015-09-24 | 2018-05-18 | 인터셉트 파마슈티컬즈, 인크. | 담즙산 유도체 제조를 위한 방법 및 중간체 |
| TN2018000106A1 (en) | 2015-10-07 | 2019-10-04 | Intercept Pharmaceuticals Inc | Farnesoid x receptor modulators |
| CN106946867B (zh) | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
| CN106995416A (zh) | 2016-01-26 | 2017-08-01 | 上海翰森生物医药科技有限公司 | Fxr激动剂及其制备方法和应用 |
| WO2017128896A1 (zh) | 2016-01-26 | 2017-08-03 | 江苏豪森药业集团有限公司 | Fxr激动剂及其制备方法和应用 |
| MY196292A (en) | 2016-01-28 | 2023-03-24 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Steroid Derivative Fxr Agonist |
| WO2017133521A1 (zh) | 2016-02-01 | 2017-08-10 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
| CN107021957A (zh) | 2016-02-01 | 2017-08-08 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
| CN108697702A (zh) | 2016-02-22 | 2018-10-23 | 诺华股份有限公司 | 使用fxr激动剂的方法 |
| US10323061B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
| US10323060B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof |
| WO2017147159A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| ES2874682T3 (es) | 2016-03-11 | 2021-11-05 | Intercept Pharmaceuticals Inc | Derivados de 3-desoxi y composiciones farmacéuticas de los mismos |
| WO2017189652A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201150A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| US10149835B2 (en) | 2016-05-18 | 2018-12-11 | Elmore Patent Law Group, P.C. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| SI3730487T1 (sl) | 2016-06-13 | 2022-08-31 | Gilead Sciences, Inc. | Azetidinski derivati kot modulatorji FXR (NR1H4) |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| AR108711A1 (es) | 2016-06-13 | 2018-09-19 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4) |
| TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| EP3954684A1 (en) | 2016-08-23 | 2022-02-16 | Ardelyx, Inc. | Process for the preparation of hormone receptor modulators for treating metabolic conditions and disorders |
| CA3039124A1 (en) | 2016-10-04 | 2018-04-12 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| CN107973790A (zh) | 2016-10-22 | 2018-05-01 | 合帕吉恩治疗公司 | 杂环fxr调节剂 |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
| CN108017636A (zh) | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| US11780885B2 (en) | 2016-11-17 | 2023-10-10 | Glaxosmithkline Biologicals Sa | Zika viral antigen constructs |
| WO2018102418A1 (en) | 2016-11-29 | 2018-06-07 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
| CN106588804B (zh) | 2016-12-09 | 2018-11-09 | 都创(上海)医药科技有限公司 | 一种作为类法尼醇x受体(fxr)的化合物的制备方法 |
| CN106632294A (zh) | 2016-12-15 | 2017-05-10 | 宁波百纳西药业有限公司 | 一种螺环化合物及其药物用途 |
| WO2018133730A1 (zh) | 2017-01-20 | 2018-07-26 | 四川科伦博泰生物医药股份有限公司 | 一种杂环化合物及其制备方法和用途 |
| CN108341822B (zh) | 2017-01-23 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和应用 |
| US10472386B2 (en) | 2017-02-14 | 2019-11-12 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR agonists and methods of use thereof |
| WO2018170173A1 (en) | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| CA3058754A1 (en) | 2017-04-07 | 2018-10-11 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonyl carbamate bile acid derivatives |
| WO2018190643A1 (en) | 2017-04-12 | 2018-10-18 | Il Dong Pharmaceutical Co., Ltd. | An isoxazole derivatives as nuclear receptor agonists and used thereof |
| AU2018272359B2 (en) | 2017-05-26 | 2022-03-03 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Lactam compound as FXR receptor agonist |
| CN110944997B (zh) | 2017-07-06 | 2021-04-09 | 轩竹生物科技有限公司 | Fxr受体激动剂 |
| US10829486B2 (en) | 2018-02-14 | 2020-11-10 | Enanta Pharmacueticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| CN109053751A (zh) | 2018-08-30 | 2018-12-21 | 成都海博锐药业有限公司 | 具有螺环结构的fxr调节剂 |
-
2016
- 2016-03-30 NZ NZ735126A patent/NZ735126A/en unknown
- 2016-03-30 RU RU2017134013A patent/RU2712099C2/ru active
- 2016-03-30 SM SM20210593T patent/SMT202100593T1/it unknown
- 2016-03-30 ES ES16774118T patent/ES2886766T3/es active Active
- 2016-03-30 WO PCT/US2016/025035 patent/WO2016161003A1/en not_active Ceased
- 2016-03-30 CA CA2981503A patent/CA2981503C/en active Active
- 2016-03-30 PT PT167741180T patent/PT3277286T/pt unknown
- 2016-03-30 HU HUE16774118A patent/HUE054960T2/hu unknown
- 2016-03-30 MY MYPI2017703433A patent/MY192135A/en unknown
- 2016-03-30 SG SG11201707263XA patent/SG11201707263XA/en unknown
- 2016-03-30 PL PL16774118T patent/PL3277286T3/pl unknown
- 2016-03-30 CN CN201680020045.2A patent/CN107427527B/zh active Active
- 2016-03-30 SI SI201631279T patent/SI3277286T1/sl unknown
- 2016-03-30 KR KR1020177030546A patent/KR102681304B1/ko active Active
- 2016-03-30 AU AU2016242861A patent/AU2016242861B2/en active Active
- 2016-03-30 MX MX2017012558A patent/MX379579B/es unknown
- 2016-03-30 SG SG10201910670RA patent/SG10201910670RA/en unknown
- 2016-03-30 US US15/085,800 patent/US10457703B2/en active Active
- 2016-03-30 RS RS20210895A patent/RS62110B1/sr unknown
- 2016-03-30 LT LTEP16774118.0T patent/LT3277286T/lt unknown
- 2016-03-30 DK DK16774118.0T patent/DK3277286T3/da active
- 2016-03-30 HR HRP20211066TT patent/HRP20211066T1/hr unknown
- 2016-03-30 JP JP2017550939A patent/JP6785788B2/ja active Active
- 2016-03-30 EP EP16774118.0A patent/EP3277286B1/en active Active
-
2017
- 2017-09-03 IL IL254288A patent/IL254288B/en active IP Right Grant
- 2017-09-04 PH PH12017501586A patent/PH12017501586B1/en unknown
- 2017-10-24 ZA ZA2017/07212A patent/ZA201707212B/en unknown
-
2019
- 2019-10-04 US US16/593,262 patent/US11040998B2/en active Active
-
2021
- 2021-04-26 ZA ZA2021/02769A patent/ZA202102769B/en unknown
- 2021-05-19 US US17/324,464 patent/US11958879B2/en active Active
- 2021-07-20 CY CY20211100660T patent/CY1124404T1/el unknown
-
2024
- 2024-03-05 US US18/595,487 patent/US20240327452A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202102769B (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| ZA201908293B (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| ZA201703759B (en) | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof | |
| SG11201703997XA (en) | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof | |
| SG11201706089RA (en) | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof | |
| ZA201707981B (en) | Compositions of obeticholic acid and methods of use | |
| IL257235A (en) | Methods for preparation of bile acids and derivatives thereof | |
| IL252596A0 (en) | History of azabicyclooctane as fxr agonists for use in the treatment of liver and gastrointestinal diseases | |
| SG11201610228RA (en) | Methods and compositions of bile acids and salts for reduction of fat | |
| IL256971A (en) | Methods for preparation of bile acids and derivatives thereof | |
| IL274796A (en) | Oxoacridinyl acetic acid derivatives and methods of use | |
| IL247529B (en) | Preparations of choline ester lipoic acid and methods of use | |
| SG11201509738RA (en) | Methods of treatment and compositions with xanthine oxidase inhibitors | |
| GB201810520D0 (en) | Branched acid emulsifer compositions and methods of use | |
| IL249463A0 (en) | Production method for (s)-2-acetyloxypropionic acid and their derivatives | |
| HK1244707B (en) | Bile acid derivatives as fxr/tgr5 agonists |